Meet ASPIRE: Galderma Rolls Out New Customer Loyalty Program
Galderma is rolling out a new loyalty program for both doctors and patients.
Tag: Galderma
All
PopularAll
Latest
Sculptra Gains EU Certification for New Body Indications
The regenerative biostimulator is now certified for use in four new body areas.
All
Latest
FDA Proposes Adding New Sunscreen Active Ingredient, Drawing Support From Dermatology Community
The agency is seeking public comment on a proposal to classify bemotrizinol as generally recognized as safe and effective for over-the-counter sunscreens.
Galderma Launches Updated Alastin Restorative Skin Complex with New Ingredients
Alastin’s enhanced serum includes a proprietary peptide and novel fat-stimulating ingredient for collagen and volume support.
Read More
Galderma Restylane Eyelight HA Filler Receives FDA Approval
Restylane Eyelight, an undereye hyaluronic acid (HA) dermal filler, is formulated with NASHA Technology for volume loss under the eyes.
Read More
Galderma Sponsors SCOPE Miami Beach 2022
Galderma is sponsoring the SCOPE Miami Beach 2022 showcase for contemporary art, offering consultations and real-time treatments to visitors.
Read More
Galderma, NBCF to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors
Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who received Galderma’s aesthetic portfolio of products in a campaign on their social channels during Breast Cancer Awareness Month in October.
Read More
Galderma Phase 3 Trial Shows Wrinkle Reducing Results
Galderma’s wrinkle treatment, RelabotulinumtoxinA, reduced wrinkles with minimal side effects in two phase III clinical studies.
Read More
Galderma to Present New Clinical Data On Portfolio of Products
Galderma will share a host of clinical and patient satisfaction data on its portfolio of products at the AMWC in Monaco.
Read More
Galderma Launches Alastin Skincare ReFORM & RePAIR COMPLEX with TriHex Technology
The newest product in the Alastin Skincare line, it’s designed to assist with recovery from aesthetic surgical body procedures.
Read More
Galderma Successfully Completes Acquisition of ALASTIN Skincare
Galderma announces that it has received antitrust clearance from the US authorities and has completed the acquisition of ALASTIN Skincare Inc.
Read More
Galderma Receives FDA Approval for New SCULPTRA Label, Offering More Options to Aesthetic Partners
Galderma announces the new label for SCULPTRA (injectable poly-L-lactic acid (PLLA)), the first and only FDA-approved PLLA facial injectable treatment that helps stimulate the skin’s own collagen production, to smooth facial wrinkles, such as smile lines.
Read More
Aesthetics Biomedical Inc Announces Perspectives Symposium
On the heels of Aesthetics Biomedical’s inaugural symposium launched in Phoenix (April 2021) comes the follow-up activation, Perspectives: The Evolution of Aesthetics, a boutique-style symposium is taking place in Orlando, Fla.
Read More
New MENTOR, Galderma Partnership Rewards Breast Implant Patients, and Practitioners
Doctors gain access to key insights about the products, utilizing business-building tools that encourage each patient’s aesthetic journey.
Read More
FDA Approves Restylane Contour
Galderma’s first and only product in the U.S. to use proprietary XpresHAn Technology for the cheeks is coming to practices this summer.
Read More
Galderma Launches Multichannel Medical Education Platform
Galderma announces the launch of its Galderma Excellence in Multichannel Medical Education (GEMME) platform with a four-part webinar series: “Unmasking Facial Skin & Dermatoses.”
Read More
COVID-19 Mask Wearing Could Be Worsening Rosacea
A recent survey conducted by Galderma suggests that the pandemic may impact rosacea patients, from worsening of signs and symptoms related to mask wearing, to reduced HCP consultations.
Read More
Latest FDA Approval Helps Galderma Expand a Growing Restylane Product Portfolio
According to reports, in 2020, online searches for chin enhancement products, like Restylane Defyne, increased by 185%.
Read More